Comparative Pharmacology
Head-to-head clinical analysis: LEVONORGESTREL versus NORGESTIMATE ETHINYL ESTRADIOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVONORGESTREL versus NORGESTIMATE ETHINYL ESTRADIOL.
LEVONORGESTREL vs NORGESTIMATE; ETHINYL ESTRADIOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic progestin that suppresses gonadotropin release (GnRH, LH, FSH) via negative feedback on the hypothalamic-pituitary-ovarian axis; inhibits ovulation, thickens cervical mucus, and alters endometrial lining.
Combination oral contraceptive containing norgestimate (a progestin) and ethinyl estradiol (an estrogen). The primary mechanism is suppression of gonadotropins (FSH and LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, preventing ovulation. Additional effects include thickening cervical mucus (inhibiting sperm penetration) and altering endometrial receptivity.
For emergency contraception: 1.5 mg orally as a single dose or 0.75 mg orally 12 hours apart. For hormonal contraception: 0.03 mg to 0.05 mg orally once daily in combined oral contraceptives; for progestin-only oral contraceptive (mini-pill): 0.03 mg orally once daily. For intrauterine system (IUD): 52 mg intrauterine device inserted for up to 5 years.
Oral, one tablet daily at the same time for 21 days, followed by 7 placebo tablets.
None Documented
None Documented
Clinical Note
moderateLevonorgestrel + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Levonorgestrel."
Clinical Note
moderateLevonorgestrel + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Levonorgestrel."
Clinical Note
moderateLevonorgestrel + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Levonorgestrel."
Clinical Note
moderateLevonorgestrel + Fluconazole
Terminal half-life: 24-30 hours (range 11-45 hours). This prolonged half-life supports once-daily or extended-cycle dosing in contraceptive formulations.
Norgestimate: terminal half-life of norelgestromin (active metabolite) is 27.6 ± 7.8 hours; ethinyl estradiol: terminal half-life is 17.5 ± 6.3 hours. Steady state achieved within 14 days.
Renal: 45-60% (metabolites), Fecal: 32-45% (unchanged and metabolites). Biliary excretion contributes to fecal elimination.
Norgestimate metabolites are primarily excreted via urine (60-80%) and feces (35-49%) as glucuronide and sulfate conjugates; ethinyl estradiol is excreted in urine (40%) and feces (60%) as conjugates.
Category C
Category D/X
Progestin
Progestin + Estrogen
"The metabolism of Fluconazole can be decreased when combined with Levonorgestrel."